Prelude Therapeutics Gears Up for Barclays Global Healthcare Event
WILMINGTON, Del. — Prelude Therapeutics Incorporated (NASDAQ: PRLD), a clinical-stage precision oncology company, has announced its participation in the upcoming Barclays 27th Annual Global Healthcare Conference. The event will take place in Miami on March 11, providing a platform for key discussions surrounding innovations in cancer treatment.
During this significant event, the CEO of Prelude, Kris Vaddi, Ph.D., along with Jane Huang, M.D., President and Chief Medical Officer, and CFO Bryant Lim, will engage in a fireside chat at 12:30 p.m. ET. This conversation will focus on the latest advancements and strategic initiatives at Prelude, highlighting the company’s commitment to enhancing patient outcomes in oncology.
For those interested in following the discussion, a live webcast of the chat will be accessible via the Company’s official website. Furthermore, the recording will be available for viewing afterward, ensuring that stakeholders can engage with the content for up to 90 days post-event.
Innovation in Oncology
Prelude Therapeutics is at the forefront of precision oncology, dedicated to creating innovative medicines aimed at addressing critical needs in cancer care. The company’s pipeline features several groundbreaking drug candidates, including first-in-class SMARCA2 degraders, which are designed to be highly selective in their action. Additionally, they are developing a potentially best-in-class CDK9 inhibitor.
Moreover, Prelude is leveraging its expertise in targeted protein degradation to develop next-generation degrader antibody conjugates, often referred to as Precision ADCs. These developments not only showcase Prelude’s innovative capabilities but also highlight its mission to make precision medicine accessible to all cancer patients in need.
About the Company
Prelude Therapeutics is grounded in the belief that every cancer patient deserves access to groundbreaking treatments. The company's efforts are focused on developing medicines for conditions that lack adequate treatment options. With a strong emphasis on collaboration, Prelude seeks to partner with other entities to accelerate the development of its innovative therapies and reach a broader patient population.
The company's commitment to research and development showcases not only its dedication but also its strategic vision for the future of oncology. By prioritizing areas of high unmet need, Prelude aims to transform the landscape of cancer treatment and improve the quality of life for patients worldwide.
Investor Relations
For those looking to connect, the investor contact for Prelude Therapeutics is Robert Doody, the Senior Vice President of Investor Relations. He is available at 484.639.7235 and can also be reached via email for inquiries regarding the company and its developments.
Community Engagement
As part of its commitment to fostering a knowledgeable community around its innovations, Prelude actively engages in informational exchanges at various conferences and presentations. This participation not only aids in disseminating vital information but also strengthens relationships within the healthcare ecosystem.
Frequently Asked Questions
What event is Prelude Therapeutics participating in?
Prelude Therapeutics is participating in the Barclays 27th Annual Global Healthcare Conference in Miami.
Who will represent Prelude at the conference?
The CEO, CTO, and CFO of Prelude will participate in a fireside chat at the event.
How can I access the webcast of the chat?
The live webcast will be available on the Company’s website during the chat and archived for future viewing.
What are some key products in Prelude's pipeline?
Prelude’s pipeline includes innovative drug candidates, such as SMARCA2 degraders and a CDK9 inhibitor.
Who can I contact for investor inquiries about Prelude?
Robert Doody is the contact for investor relations, reachable at 484.639.7235 or via email.